Final draft guidance published by the health technology assessment (HTA) body, NICE, has opened the door for greater use of biosimilar adalimumab, etanercept and infliximab in England by recommending that these biologic molecules be used on the National Health Service to treat moderate as well as severe rheumatoid arthritis.
NICE Decision On Arthritis Opens Door For Biosimilars In England
UK Recommends Treating Moderate Rheumatoid Arthritis With Three Biologic Molecules
A decision by health technology assessment body NICE opens the door to broaden the use of adalimumab, etanercept and infliximab by using them to treat moderate as well as severe rheumatoid arthritis.
More from United Kingdom
• By
Pharmaceutical companies are being encouraged to reach out to NICE in relation to its HTA Innovation Lab, which provides a sandbox environment in which the health technology assessment body can test new methods of evaluating “innovative and disruptive” therapies.
• By
Health technology assessment body NICE said it has taken on feedback about the implications of allowing higher cost-effectiveness thresholds for some medicines after senior health economists offered diverging views on its methods.
• By
Cell and gene therapy manufacturers must consider the practicalities of their product within the context of a health care system before it comes onto the market to be successful, experts from Novartis, AstraZeneca and England’s National Health Service say.
• By
The UK branded drug industry is calling for adjustments to be made to the UK voluntary scheme framework for branded medicines, after the payment rate increased to 22.9% for 2025. Meanwhile, the generics industry says the scheme is functioning “as intended” and opposes any changes.
More from Europe
• By
The European Medicines Agency has recommended five drugs for EU-wide approval , including Averoa’s Xoanacyl for concomitant hyperphosphatemia. Two companies have withdrawn their marketing authorization applications.
• By
Eli Lilly’ will request a re-examination after the European Medicines Agency declined to recommend its Alzheimer’s disease drug Kisunla for EU approval.
• By
The new global GCP guideline, ICH E6(R3), enables researchers and clinical trial administrators to tailor their documentation processes, but also opens the door for more scrutiny during GCP inspections.